Autoimmune and inflammatory disorder therapy

US9301961B2 · kind B2 · utility

Assignee

• Katholieke Universiteit Leuven, KU LEUVEN R&D · BE

Inventors

• Jean Herman · Heverlee, BE
• Thierry Louat · Leuven, BE
• Qiuya Huang · Leuven, BE
• Bart Vanderhoydonck · Diest, BE
• Mark Waer · Heverlee, BE
• Piet Herdewijn · Heverlee, BE

Key dates

• Filing date: Sep 7, 2012
• Grant date: Apr 5, 2016
• Expiry date: Dec 15, 2032

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds that bind to phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) and inhibit the binding of PI4KIIIβ to its substrate and/or inhibit PI4KIIIβ activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating and/or preventing those pathological conditions, which comprises measuring the inhibition of PI4KIIIβ activity, is also disclosed.